Clinical Trial Results: Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating ramucirumab plus pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-08-17